Current Report Filing (8-k)
May 08 2023 - 04:10PM
Edgar (US Regulatory)
false000107049400010704942023-05-082023-05-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
Date of Report (Date of earliest event reported):
May 08, 2023
|
Acadia Pharmaceuticals Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
000-50768
|
06-1376651
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
12830 El Camino Real, Suite 400
|
|
San Diego,
California
|
|
92130
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
Registrant’s Telephone Number, Including Area Code:
(858)
558-2871
|
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
|
ACAD
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 8, 2023, Acadia Pharmaceuticals Inc. issued a press release
announcing its financial results for the three months ended March
31, 2023. A copy of this press release is furnished herewith as
Exhibit 99.1. Pursuant to the rules and regulations of the
Securities and Exchange Commission, such exhibit and the
information set forth therein and in this Item 2.02 have been
furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to liability under that
section nor shall they be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such filing regardless of any general incorporation
language.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
Acadia Pharmaceuticals Inc.
|
|
|
|
|
Date:
|
May 8, 2023
|
By:
|
/s/ Austin D. Kim
|
|
|
|
Austin D. Kim
Executive Vice President, General Counsel &
Secretary
|
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2023 to Sep 2023
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2022 to Sep 2023